Background The introduction of crosslinked ultra-high molecular weight polyethylene (XLPE) acetabular liners has been very successful, with decreased wear and reduction in the rates of revision hip arthroplasties. XLPE is the preferred articulation for most surgeons; however, there are concerns about the long-term performance of XLPE liners created with different manufacturing processes, which may lead to time-dependent failure, including accelerated wear, after several years. Questions/purposes (1) What is the amount and rate of wear during the first 10 years using radiostereometric analysis (RSA) measurements of patients who had THAs that included a second-generation XLPE bearing? (2) Does the rate of wear change after 5 years in situ? Methods This is a brief follow-up of a previous RSA study.In that study, we prospectively enrolled 21 patients with osteoarthritis who underwent primary cementless THA with an XLPE acetabular liner (three cycles of 3Mrad annealed) and 32-mm articulation. That group represented 44% of the 48 THAs performed by the surgeon at the hospital where RSA was available; 16 had cemented hips, leaving 32 who were invited to participate in this study. Of those, 11 lived rurally and declined to participate, leaving 21 patients who were included in the initial study. Since then, three patientsThe institution of one or more of the authors (DGC) has received, during the study period, funding from Stryker Australia. The institution of one or more of the authors (SAC) has received, during the study period, research funding from Zimmer. One of the authors (DGC) certifies receipt of personal payments or benefits, during the study period, in an amount of USD 10,000 to USD 100,000 from Smith & Nephew; in an amount of USD 10,000 to USD 100,00 from Surgical Devices Pty Ltd. One of the authors (DGC) certifies holding stocks in Amplitude Orthopaedics as well as performing nonremunerated consulting for DePuy, Smith & Nephew, Mathys Orthopaedics, and Zimmer. This project was undertaken while one author (SAC) held a Royal Adelaide Hospital Mary Overton Fellowship in an amount of USD 10,000 to USD 100,000. All ICMJE Conflict of Interest Forms for authors and Clinical Orthopaedics and Related Research® editors and board members are on file with the publication and can be viewed on request. Clinical Orthopaedics and Related Research® neither advocates nor endorses the use of any treatment, drug, or device. Readers are encouraged to always seek additional information, including FDA approval status, of any drug or device before clinical use. Ethical approval for this study was obtained from Calvary Wakefield Hospital, Adelaide, Australia (number 2007 P1).